Karlijn Hummelink
0000-0003-4371-8904
Publication & Citation Trends
Most Cited Works
Publications
143 total
Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer PDF
Cited by 25
OpenAlex
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer PDF
Cited by 3
OpenAlex
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer PDF
Cited by 28
OpenAlex
A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics PDF
Cited by 5
OpenAlex
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer PDF
Cited by 3
OpenAlex
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer. OA
Cited by 2
Semantic Scholar
Abstract 1393: Persistent mutation burden drives sustained anti-tumor immune responses in human cancers
Cited by 1
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(132)
Immunotherapy and Immune Responses
(63)
Cancer Genomics and Diagnostics
(62)
Lung Cancer Research Studies
(50)
Lung Cancer Treatments and Mutations
(38)
Frequent Co-Authors
Affiliations
The University of Texas MD Anderson Cancer Center
Dutch Cancer Society
University Hospital of Basel
The Netherlands Cancer Institute
University of Oxford